FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361947053> ?p ?o ?g. }

• W4361947053 abstract "<div>AbstractPurpose:<p>This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with extensive-stage (ED) small cell lung cancer (SCLC) and other solid tumors.</p>Patients and Methods:<p>The 3 + 3 design was used for dose escalation of oral veliparib in combination with carboplatin (AUC 5 on day 1) and etoposide (100 mg/m² on days 1–3) in 21-day cycles. Veliparib dose was explored from 80 to 240 mg b.i.d. on 7-day, 14-day, or continuous schedules. Patients without disease progression continued on maintenance monotherapy (veliparib 400 mg b.i.d.) until disease progression or unacceptable toxicity.</p>Results:<p>Thirty-nine patients were enrolled to determine the recommended phase II dose of 240 mg veliparib for 14 days combined with carboplatin and etoposide based on long-term tolerability. Dose-limiting toxicity occurred in 1 patient (grade 2 toxic motor polyneuropathy) at veliparib 240 mg b.i.d. for 7 days. Most common adverse events related to veliparib were nausea (39%), fatigue (39%), and hematologic toxicities. Continuous dosing of veliparib 240 mg b.i.d. with carboplatin and etoposide resulted in excessive chemotherapy dose delays due to hematologic toxicity (grade 3/4 neutropenia/thrombocytopenia). Etoposide pharmacokinetics was not affected by veliparib. Confirmed responses occurred in 17 of 39 (44%) and 16 of 25 (64%) of all enrolled and ED SCLC patients, respectively. At the RP2D, confirmed responses occurred in 6 of 13 (46%) and 5 of 6 (83%) of all enrolled and ED SCLC patients, respectively.</p>Conclusions:<p>Veliparib (240 mg b.i.d. 14 days) plus carboplatin/etoposide can be safely combined. Phase II of this study is ongoing in first-line patients with ED SCLC.</p></div>" @default.
• W4361947053 created "2023-04-05" @default.
• W4361947053 creator A5000359400 @default.
• W4361947053 creator A5017960622 @default.
• W4361947053 creator A5033776778 @default.
• W4361947053 creator A5034652107 @default.
• W4361947053 creator A5035562927 @default.
• W4361947053 creator A5045350689 @default.
• W4361947053 creator A5045732752 @default.
• W4361947053 creator A5059711568 @default.
• W4361947053 creator A5063627915 @default.
• W4361947053 creator A5067755477 @default.
• W4361947053 creator A5075037954 @default.
• W4361947053 creator A5078332643 @default.
• W4361947053 creator A5081588858 @default.
• W4361947053 creator A5082384956 @default.
• W4361947053 creator A5082517668 @default.
• W4361947053 creator A5083922534 @default.
• W4361947053 creator A5090452503 @default.
• W4361947053 date "2023-03-31" @default.
• W4361947053 modified "2023-09-25" @default.
• W4361947053 title "Data from A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors" @default.
• W4361947053 doi "https://doi.org/10.1158/1078-0432.c.6529248" @default.
• W4361947053 hasPublicationYear "2023" @default.
• W4361947053 type Work @default.
• W4361947053 citedByCount "0" @default.
• W4361947053 crossrefType "posted-content" @default.
• W4361947053 hasAuthorship W4361947053A5000359400 @default.
• W4361947053 hasAuthorship W4361947053A5017960622 @default.
• W4361947053 hasAuthorship W4361947053A5033776778 @default.
• W4361947053 hasAuthorship W4361947053A5034652107 @default.
• W4361947053 hasAuthorship W4361947053A5035562927 @default.
• W4361947053 hasAuthorship W4361947053A5045350689 @default.
• W4361947053 hasAuthorship W4361947053A5045732752 @default.
• W4361947053 hasAuthorship W4361947053A5059711568 @default.
• W4361947053 hasAuthorship W4361947053A5063627915 @default.
• W4361947053 hasAuthorship W4361947053A5067755477 @default.
• W4361947053 hasAuthorship W4361947053A5075037954 @default.
• W4361947053 hasAuthorship W4361947053A5078332643 @default.
• W4361947053 hasAuthorship W4361947053A5081588858 @default.
• W4361947053 hasAuthorship W4361947053A5082384956 @default.
• W4361947053 hasAuthorship W4361947053A5082517668 @default.
• W4361947053 hasAuthorship W4361947053A5083922534 @default.
• W4361947053 hasAuthorship W4361947053A5090452503 @default.
• W4361947053 hasConcept C104317684 @default.
• W4361947053 hasConcept C112705442 @default.
• W4361947053 hasConcept C126322002 @default.
• W4361947053 hasConcept C143998085 @default.
• W4361947053 hasConcept C182979987 @default.
• W4361947053 hasConcept C185592680 @default.
• W4361947053 hasConcept C197934379 @default.
• W4361947053 hasConcept C2776694085 @default.
• W4361947053 hasConcept C2778119113 @default.
• W4361947053 hasConcept C2778239845 @default.
• W4361947053 hasConcept C2778375690 @default.
• W4361947053 hasConcept C2781312401 @default.
• W4361947053 hasConcept C2781451048 @default.
• W4361947053 hasConcept C29730261 @default.
• W4361947053 hasConcept C55493867 @default.
• W4361947053 hasConcept C71924100 @default.
• W4361947053 hasConcept C82381507 @default.
• W4361947053 hasConcept C98274493 @default.
• W4361947053 hasConceptScore W4361947053C104317684 @default.
• W4361947053 hasConceptScore W4361947053C112705442 @default.
• W4361947053 hasConceptScore W4361947053C126322002 @default.
• W4361947053 hasConceptScore W4361947053C143998085 @default.
• W4361947053 hasConceptScore W4361947053C182979987 @default.
• W4361947053 hasConceptScore W4361947053C185592680 @default.
• W4361947053 hasConceptScore W4361947053C197934379 @default.
• W4361947053 hasConceptScore W4361947053C2776694085 @default.
• W4361947053 hasConceptScore W4361947053C2778119113 @default.
• W4361947053 hasConceptScore W4361947053C2778239845 @default.
• W4361947053 hasConceptScore W4361947053C2778375690 @default.
• W4361947053 hasConceptScore W4361947053C2781312401 @default.
• W4361947053 hasConceptScore W4361947053C2781451048 @default.
• W4361947053 hasConceptScore W4361947053C29730261 @default.
• W4361947053 hasConceptScore W4361947053C55493867 @default.
• W4361947053 hasConceptScore W4361947053C71924100 @default.
• W4361947053 hasConceptScore W4361947053C82381507 @default.
• W4361947053 hasConceptScore W4361947053C98274493 @default.
• W4361947053 hasLocation W43619470531 @default.
• W4361947053 hasOpenAccess W4361947053 @default.
• W4361947053 hasPrimaryLocation W43619470531 @default.
• W4361947053 hasRelatedWork W1594141262 @default.
• W4361947053 hasRelatedWork W1970709330 @default.
• W4361947053 hasRelatedWork W2030471493 @default.
• W4361947053 hasRelatedWork W2074207917 @default.
• W4361947053 hasRelatedWork W2108334876 @default.
• W4361947053 hasRelatedWork W2120734114 @default.
• W4361947053 hasRelatedWork W2357464014 @default.
• W4361947053 hasRelatedWork W4361889571 @default.
• W4361947053 hasRelatedWork W4361936923 @default.
• W4361947053 hasRelatedWork W4361958287 @default.
• W4361947053 isParatext "false" @default.
• W4361947053 isRetracted "false" @default.
• W4361947053 workType "article" @default.